Flag of the European Union EU Clinical Trials Register Help

Clinical trials for McDonald criteria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    274 result(s) found for: McDonald criteria. Displaying page 3 of 14.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-024017-31 Sponsor Protocol Number: CFTY720DIT02 Start Date*: 2011-03-15
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005418-31 Sponsor Protocol Number: COMB157G2301 Start Date*: 2016-10-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) GB (Completed) SE (Completed) DK (Completed) CZ (Completed) SK (Completed) ES (Completed) NL (Completed) EE (Completed) BG (Completed) GR (Completed) PL (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002937-31 Sponsor Protocol Number: MA30143 Start Date*: 2017-09-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Completed) BE (Completed) HU (Completed) PL (Completed) SK (Completed) ES (Ongoing) BG (Completed) SI (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000647-30 Sponsor Protocol Number: EFC16645 Start Date*: 2020-08-27
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis
    Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) FR (Completed) DE (Restarted) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) FI (Completed) DK (Completed) BE (Completed) LT (Completed) AT (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000254-11 Sponsor Protocol Number: 33375 Start Date*: 2014-03-28
    Sponsor Name:Department of Neurology
    Full Title: ROLE OF ENDOTHELIAL INFLAMMATION IN DEMYELINATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
    Medical condition: Mulple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019028-30 Sponsor Protocol Number: CFTY720D2320 Start Date*: 2010-07-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 3-month blinded, randomized, multicenter, placebocontrolled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus t...
    Medical condition: Relapsing forms of multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048393 Multiple sclerosis relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) FR (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005148-28 Sponsor Protocol Number: 25643 Start Date*: 2005-05-26
    Sponsor Name:Merck Serono International S.A.
    Full Title: A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DK (Completed) EE (Completed) CZ (Completed) BE (Completed) IT (Completed) AT (Completed) SK (Completed) LT (Completed) DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2004-002571-16 Sponsor Protocol Number: MBP8298-01 Amendment 04 Start Date*: 2007-06-29
    Sponsor Name:BioMS Technology Corp
    Full Title: A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.
    Medical condition: Secondary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) EE (Completed) NL (Completed) LT (Prematurely Ended) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001947-70 Sponsor Protocol Number: MBP8298-RR-01 Start Date*: 2006-09-14
    Sponsor Name:BioMS Technology Corp.
    Full Title: A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002728-33 Sponsor Protocol Number: CUPID2005 Start Date*: 2006-02-28
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: Cannabinoid Use in Progressive Inflammatory brain Disease
    Medical condition: Progressive multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011516-37 Sponsor Protocol Number: 14022009 Start Date*: 2009-05-29
    Sponsor Name:Danish Multiple Sclerosis Research Centre
    Full Title: Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multipl...
    Medical condition: Multiple Sclerosis, with primary and secondary progressive courses.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004475-36 Sponsor Protocol Number: DC-002 Start Date*: 2012-05-19
    Sponsor Name:Delta Crystallon B.V.
    Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patient...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005419-33 Sponsor Protocol Number: COMB157G2302 Start Date*: 2016-10-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) FI (Completed) GB (Completed) AT (Completed) CZ (Completed) PT (Completed) SK (Completed) ES (Completed) LV (Completed) LT (Completed) BG (Completed) FR (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000283-41 Sponsor Protocol Number: FUMAPMS2016 Start Date*: 2016-09-12
    Sponsor Name:Finn Sellebjerg
    Full Title: Dimethyl fumarate treatment of primary progressive multiple sclerosis
    Medical condition: Primary progressive multiple sclerosis (PPMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005592-14 Sponsor Protocol Number: 26 Start Date*: 2006-07-27
    Sponsor Name:IFSgGmbH, Institute for clinical research
    Full Title: Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PRO...
    Medical condition: Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001567-55 Sponsor Protocol Number: DAC-1012 Start Date*: 2006-06-23
    Sponsor Name:Protein Design Labs, Inc.
    Full Title: A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis
    Medical condition: This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000182-31 Sponsor Protocol Number: CHDR1438 Start Date*: 2015-02-11
    Sponsor Name:CHDR
    Full Title: A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral ...
    Medical condition: Multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000645-14 Sponsor Protocol Number: EFC16035 Start Date*: 2020-10-13
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
    Medical condition: Primary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BG (Trial now transitioned) EE (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) NO (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) LV (Completed) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005249-12 Sponsor Protocol Number: EFC11759 Start Date*: 2014-08-13
    Sponsor Name:Genzyme Corporation
    Full Title: A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Onc...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) BE (Completed) ES (Completed) GR (Completed) PL (Completed) GB (GB - no longer in EU/EEA) FR (Completed) LT (Completed) Outside EU/EEA IE (Completed) NL (Completed) BG (Completed) PT (Completed) SI (Completed) IT (Not Authorised)
    Trial results: View results
    EudraCT Number: 2019-001341-40 Sponsor Protocol Number: COMB157G23101 Start Date*: 2020-05-07
    Sponsor Name:Novartis Pharma AG
    Full Title: A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes(PRO) in patients with relapsing multiple sclerosis (RMS) transi...
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Trial now transitioned) GR (Completed) HU (Completed) SK (Trial now transitioned) BE (Completed) PT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) NO (Completed) AT (Completed) PL (Trial now transitioned) IT (Completed) SI (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 23:57:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA